Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian J. Druker

Showing results (11-20 of 278) with videos related to

Pageof 28
Sort By:
Blood|December 25, 2004
The development of imatinib as a therapeutic agent for chronic myeloid leukemiaMichael Deininger, Elisabeth Buchdunger, Brian J Druker
Pharmacological Reviews|July 19, 2003
Specific targeted therapy of chronic myelogenous leukemia with imatinibMichael W N Deininger, Brian J Druker
Cancer Cell|August 25, 2004
SRCircumventing imatinib resistanceMichael W N Deininger, Brian J Druker
Current Opinion in Genetics & Development|December 14, 2005
Targeted CML therapy: controlling drug resistance, seeking cureThomas O'Hare, Amie S Corbin, Brian J Druker
Leukemia Research|March 24, 2004
Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remissionMichael J Mauro, Brian J Druker, Richard T Maziarz
Cancer Cell|April 15, 2020
Response and Resistance to BCR-ABL1-Targeted TherapiesTheodore P Braun, Christopher A Eide, Brian J Druker
Cancer Investigation|August 7, 2003
STI571 as a targeted therapy for CMLMichael E O'Dwyer, Michael J Mauro, Brian J Druker
Annual Review of Medicine|January 31, 2002
Recent advancements in the treatment of chronic myelogenous leukemiaMichael E O'Dwyer, Michael J Mauro, Brian J Druker
Annals of Internal Medicine|May 21, 2003
Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeuticsRazelle Kurzrock, Hagop M Kantarjian, Brian J Druker, et al.
Obstetrics and Gynecology|April 7, 2017
Maternal, Fetal, and Neonatal Imatinib Levels With Treatment of Chronic Myeloid Leukemia in PregnancyRichard M Burwick, Kelly Kuo, Diana Brewer, et al.
Pageof 28

Showing results (11-20 of 278) with videos related to

Sort By:
Pageof 28
Blood|December 25, 2004
The development of imatinib as a therapeutic agent for chronic myeloid leukemiaMichael Deininger, Elisabeth Buchdunger, Brian J Druker
Pharmacological Reviews|July 19, 2003
Specific targeted therapy of chronic myelogenous leukemia with imatinibMichael W N Deininger, Brian J Druker
Cancer Cell|August 25, 2004
SRCircumventing imatinib resistanceMichael W N Deininger, Brian J Druker
Current Opinion in Genetics & Development|December 14, 2005
Targeted CML therapy: controlling drug resistance, seeking cureThomas O'Hare, Amie S Corbin, Brian J Druker
Leukemia Research|March 24, 2004
Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remissionMichael J Mauro, Brian J Druker, Richard T Maziarz
Cancer Cell|April 15, 2020
Response and Resistance to BCR-ABL1-Targeted TherapiesTheodore P Braun, Christopher A Eide, Brian J Druker
Cancer Investigation|August 7, 2003
STI571 as a targeted therapy for CMLMichael E O'Dwyer, Michael J Mauro, Brian J Druker
Annual Review of Medicine|January 31, 2002
Recent advancements in the treatment of chronic myelogenous leukemiaMichael E O'Dwyer, Michael J Mauro, Brian J Druker
Annals of Internal Medicine|May 21, 2003
Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeuticsRazelle Kurzrock, Hagop M Kantarjian, Brian J Druker, et al.
Obstetrics and Gynecology|April 7, 2017
Maternal, Fetal, and Neonatal Imatinib Levels With Treatment of Chronic Myeloid Leukemia in PregnancyRichard M Burwick, Kelly Kuo, Diana Brewer, et al.
Pageof 28